Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report

Figures & data

Table 1 Next-Generation Sequencing Results

Characteristics	Somatic Gene				Germline Gene
	ARID1A	MAPK8IP1	HER2	PAX8	CHEK2
Genovariation	c.5161C>T	c.1117G>T	Copy number amplification	Copy number amplification	c.1116_1117insC
Amino acid variation	p.R1721*	p.A373S	/	/	p.K373Qfs*22
Gene region	EX20	EX5	/	/	EX11
Frequency	15.25%	5.75%	/	/	/
Transcript	NM_006015.4	NM_005456.3	/	/	NM007194.3

Note: *Means termination codon.

Figure 1 Treatment timeline.

Abbreviations: CR, complete response; PR, partial response; *Means chemotherapy cycles.

Figure 2 Radiological imaging of the patient before and after the combination treatment of olaparib, pembrolizumab, and bevacizumab. (A) Computed tomography (CT) performed on December 4, 2020, showing recurrence before treatment (baseline). (B and C) CT performed on March 17, 2021 (B) and May 31, 2021, (C) showing the reduced tumor size after four and eight cycles of combination therapy, respectively. (D) CT performed on December 2, 2021, identified little residue of the tumor. The red circle indicates the tumor.